Logo

Pfizer to Acquire ReViral for ~$525M

Share this
Pfizer to Acquire ReViral for ~$525M

Pfizer to Acquire ReViral for ~$525M

Shots:

  • Pfizer to acquire ReViral for a total consideration of ~$525M including upfront and development milestones. The program is expected to generate ~$1.5B in revenue, if successful
  • The acquisition strengthens Pfizer’s capabilities in R&D for infectious disease with a complementary strategy & also expands its anti-infective pipeline to improve patient outcomes for RSV infections and prevent illness through vaccination
  • Pfizer will use its R&D, manufacturing, and commercialization expertise for the clinical development of a therapy to treat RSV disease.  Sisunatovir is currently in P-II clinical development in infants & has received FTD from the US FDA

Ref: Businesswire | Image: Pfizer

Click here to­ read the full press release 

Neha

Neha Madan is a content writer at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions